Johnson & Johnson Innovative Medicine: Findings Presented at ACC.24 Showed XARELTO (rivaroxaban) Reduced the Risk of Clinically Significant Bleeding and Net Adverse Clinical Events or Rehospitalization
April 08, 2024
April 08, 2024
NEW BRUNSWICK, New Jersey, April 8 (TNSres) -- Johnson and Johnson Innovative Medicine (formerly the Janssen Pharmaceutical Companies of Johnson and Johnson) issued the following news release:
* * *
New exploratory analysis demonstrates consistent results of XARELTO (R) in treating elderly and non- elderly patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention
XARELTO(R) is one of the most studied oral anticoagulants, an . . .
* * *
New exploratory analysis demonstrates consistent results of XARELTO (R) in treating elderly and non- elderly patients with nonvalvular atrial fibrillation undergoing percutaneous coronary intervention
XARELTO(R) is one of the most studied oral anticoagulants, an . . .